Prevention of Hospital-Acquired Hyponatremia: What Can We Learn From Children?

Curriculum:
Paul - Hyponatremia
Credits:
0.5 AMA PRA Category 1 Credits
Launch Date:
31-May-11
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

No Primary Audience Was Provided.

Relevant Terms:

No Primary Audience Was Provided.

Leonard Feldman, MD

Chair and Planner
Leonard Feldman, MD
Assistant Professor of Medicine
Johns Hopkins University School of Medicine
Med-Peds Urban Health Residency Program Director
Associate Program Director, Osler Medical Residency
Director, Comprehensive General Medicine Consult Service
Editor, John Hopkins Consultative Medicine Essentials for Hospitalists
Baltimore, Maryland

Leonard Feldman, MD, a member of the Active Staff at Johns Hopkins Hospital, is an Assistant Professor in Internal Medicine and Pediatrics and a hospitalist in the Division of General Internal Medicine at Johns Hopkins University School of Medicine. He serves as the Program Director for the Johns Hopkins Med-Peds Urban Health Residency, as an Associate Program Director for the Osler Internal Medicine Residency, and as the Director of the General Medicine Comprehensive Consultation Service.

Dr. Feldman graduated with a BA in Political Science from Brown University and then received his medical degree from the University of Maryland School of Medicine. Dr. Feldman completed his internship and residency in Internal Medicine and Pediatrics at the University of North (UNC). He then served as chief resident in internal medicine at UNC.

As a hospitalist and a clinical skills specialist, Dr. Feldman has focused his research on consult medicine, safe transitions, on-line education, and systematic reviews. Other interests include patient education, urban medicine, evidence-based medicine, and quality improvement. He is the editor-in-chief for the Johns Hopkins Consultative Medicine Essentials for Hospitalists and an Associate Editor for the Journal of Hospital Medicine.
 
Dr. Feldman has participated as a co-investigator in 2 Evidence-Based Practice Center Agency for Healthcare Research and Quality reports: Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus and Systematic Review: Comparative Effectiveness and Safety of Premixed Insulin Analogues in Type 2 Diabetes. Both reports resulted in publication in the Annals of Internal Medicine. He is also the co-principal investigator for the Maryland sickle cell disease treatment demonstration project.

Board-certified in internal medicine and pediatrics, Dr. Feldman is a member of the Med-Peds Program Director's Association, the Association of Program Directors of Internal Medicine, the Society for General Internal Medicine, the American Academy of Pediatrics (AAP), the American College of Physicians (ACP), and the Society of Hospital Medicine (SHM).
 
Dr. Feldman is a fellow of the AAP and the ACP and a senior fellow of SHM. 
 
Feel free to contact Dr. Feldman at LF@jhmi.edu.

Michael L. Moritz, MD

Participating Faculty
Michael L. Moritz, MD
Clinical Director of Pediatric Nephrology
Medical Director, Pediatric Dialysis
Associate Professor of Pediatrics
University of Pittsburgh School of Medicine
Division of Pediatric Nephrology
Pittsburgh, Pennsylvania

Michael L. Moritz, MD, completed his fellowship in pediatric nephrology at Texas Children's Hospital in 1997. While there, he began collaboration with Carlos Ayus, MD, on the epidemiology, prevention, and treatment of disorders of sodium and water metabolism in children. From there he moved on to the Albert Einstein College of Medicine where he was director of the pediatric dialysis unit. He joined the Children's Hospital of Pittsburgh of UPMC faculty in 1999. Dr Moritz has been recognized for his outstanding clinical work, teaching, and research. He was recognized as an outstanding clinical faculty by the Department Chairmen in 2003. He received the ACES award in 2006. He has won teaching awards at the University of Chicago and Children's Hospital of Pittsburgh.

Dr. Moritz's primary research interests are in sodium and water metabolism in children. He has done seminal work in the field, pointing out the dangers of using hypotonic fluids in hospitalized children as it has resulted in numerous cases of iatrogenic death or permanent neurological injury. Dr. Moritz and Dr. Ayus were the first to recommend the use of 0.9% sodium chloride in maintenance fluids in hospitalized children as prophylaxis against developing hospital acquired hyponatremia. He has been the primary advocate in this field writing many review articles, editorials, and letters to the editor in order to increase awareness of this serious problem. Dr. Moritz also has expertise in the epidemiology and treatment of hypernatremia in children.

Dr. Moritz is active in teaching of medical students, residents and fellows. He is an Associate Professor of Pediatrics at the University of Pittsburgh School of Medicine and the Clinic Director of Pediatric Nephrology and Medical Director of Pediatric Dialysis at the Children's Hospital of Pittsburgh of UPMC.

Derek M. Fine, MD

Derek M. Fine, MD (Planner)
Associate Professor of Medicine
Division of Nephrology
Johns Hopkins University School of Medicine
Baltimore, Maryland

Derek M. Fine, MD, is Associate Professor of Medicine and Nephrology Fellowship Program Director at the Johns Hopkins University School of Medicine. He received his bachelor of science at the University of Miami and his MD at Johns Hopkins University School of Medicine. He completed an Internal Medicine residency and a Nephrology fellowship at The Johns Hopkins University/Johns Hopkins Hospital. His clinical interests include systemic lupus erythematosus (SLE)-, HIV-, and scleroderma-related kidney disease; glomerular diseases; rhabdomyolysis; and toxins and kidney disease. Dr. Fine's research has predominantly focused on optimizing the diagnosis and management glomerular kidney diseases, particularly HIV- and SLE-related kidney disease.
1. Describe the physiologic and pharmacologic mechanisms that lead to the development of hyponatremia. (MK)*
2. Assess the safety and efficacy of current and emerging therapies for the management of hyponatremia. (MK, PC)*
3. Identify appropriate management approaches for patients experiencing hyponatremia in the hospital setting. (MK, PC, PB)*